Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective

References

• Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418-23
   PubMed Web of Science ®Google Scholar
• Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol 2002;22:441-8
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Pereira BJ, Collins AJ, et al. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001;37:1177-83
   PubMed Web of Science ®Google Scholar
• White SL, Cass A, Atkins RC, et al. Chronic kidney disease in the general population. Adv Chronic Kidney Dis 2005;12:5-13
   PubMed Web of Science ®Google Scholar
• McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scott Med J 1997;42:99-104
   PubMed Web of Science ®Google Scholar
• Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens 1996;5:219-23
   PubMedGoogle Scholar
• Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003;16:118-27
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Lewis JB. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol 2003;7:1-8
   PubMedGoogle Scholar
• Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005;18:100-5S
   Web of Science ®Google Scholar
• Bakris GL. Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005;18:112-19S
   Web of Science ®Google Scholar
• USRDS. Patient Mortality and Survival. US Renal Data System, USRDS 1998, Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1998: 63-78. Available from: www.usrds.org. Accessed May 13, 2004
   Google Scholar
• Bloembergen WE. Cardiac disease in chronic uremia: epidemiology. Adv Ren Replace Ther 1997;4:185-93
   PubMedGoogle Scholar
• Barrett BJ. Applying multiple interventions in chronic kidney disease. Semin Dial 2003;16:157-64
   PubMed Web of Science ®Google Scholar
• Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004;17:209-16
   PubMed Web of Science ®Google Scholar
• Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006;69:33-43
   PubMed Web of Science ®Google Scholar
• Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003;24:2054-60
   PubMed Web of Science ®Google Scholar
• Daisley-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy 1996;16:619-30
   PubMed Web of Science ®Google Scholar
• Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21
   PubMed Web of Science ®Google Scholar
• Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000;320:100-6
   PubMed Web of Science ®Google Scholar
• Tuma SN, Martin RR, Mallette LE, et al. Augmented polymorphonuclear chemiluminescence in patients with secondary hyperparathyroidism. J Lab Clin Med 1981;97:291-8
   PubMed Web of Science ®Google Scholar
• Chervu I, Kiersztein M, Alexiewicz JM, et al. Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. Kidney Int 1992;41:1501-5
   PubMed Web of Science ®Google Scholar
• Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997;30:606-20
   PubMed Web of Science ®Google Scholar
• Huraib S, Tanimu D, Romeh SA, et al. Effects of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Am J Kidney Dis 1998;32:1036-40
   PubMed Web of Science ®Google Scholar
• Rubinger D, Friedlander MM, Silver J, et al. Progressive vascular calcification with necrosis of extremities in hemodialysis patients: a possible role of iron overload. Am J Kidney Dis 1986;VII:125-9
   Web of Science ®Google Scholar
• Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004;19:V2-8
   PubMed Web of Science ®Google Scholar
• Zandi-Nejad K, Brenner BM. Strategies to retard the progression of chronic kidney disease. Med Clin North Am. 2005;89:489-509
   PubMed Web of Science ®Google Scholar
• Mix TC, St Peter WL, Ebben J, et al. Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 2003;42:972-81
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-8029
   PubMed Web of Science ®Google Scholar
• Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complicat 2004;18:18-26
   PubMed Web of Science ®Google Scholar
• Warnock DG. Inclusion of albumin as a target in therapy guidelines: guidelines for chronic kidney disease. Kidney Int 2004;92:121-3
   Web of Science ®Google Scholar
• Llach F, Velasquez-Forero F. Secondary hyperparathyroidism in chronic renal failure; pathogenic and clinical aspects. Am J Kidney Dis 2001;38:20-33
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kid Dis 1995;26:852-60
   PubMed Web of Science ®Google Scholar
• Finch J, Brown A, Slatolpolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999;10:980-5
   PubMed Web of Science ®Google Scholar
• Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002;40:1283-8
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzales EA, Gellens M, et al. 19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-32
   PubMed Web of Science ®Google Scholar
• Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-23
   PubMed Web of Science ®Google Scholar
• Sprague S, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38:S45-50
   PubMed Web of Science ®Google Scholar
• Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823-8
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
   PubMed Web of Science ®Google Scholar
• Dobrez D, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical setting. Nephrol Dial Transplant 2004;5:1174-81
   Web of Science ®Google Scholar
• Nuijten, MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998;4:433-55
   Web of Science ®Google Scholar
• TreeAge Software, Inc. Decision Analysis by TreeAge (DATA) Software. Williamstown, MA, 1996
   Google Scholar
• Sonnenberg, F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• http://www.westegg.com/inflation
   Google Scholar
• Nuijten MJC. Data management in modelling studies: the selection of data sources. Pharmacoeconomics 1998;3:305-16
   Web of Science ®Google Scholar
• Keith D, Nicholas G, Gullion C, et al. Mortality of chronic kidney disease in a large HMO population. J Am Soc Nephrol 2002;13:620A
   Google Scholar
• Bakris GL, Levin A, Molitch M, et al. Disturbances of serum 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] in patients with chronic kidney disease. J Am Soc Nephi 2005;16:495A
   Web of Science ®Google Scholar
• Smith D, Gullion C, Nichols G, et al. Cost of medical care for CKD and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15:1300-6
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Marx SE, Schumock G, et al. Examination of outcomes and costs of care among patient with chronic kidney disease and secondary hyperparathyroidism. J Am Soc Nephrol 2006;17:647A
   Google Scholar
• Jones C, Roderick P, Harris S, et al. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis 2006;47:103-14
   PubMed Web of Science ®Google Scholar
• Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. J Am Med Assoc 2003;290:3101-14
   PubMed Web of Science ®Google Scholar
• Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7
   PubMed Web of Science ®Google Scholar
• Kiberd BA, Jindal KK. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 1998;31:49-54
   PubMed Web of Science ®Google Scholar
• Hogan TJ, Elliott WJ, Seto AH, et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002;20:37-47
   PubMed Web of Science ®Google Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8
   PubMed Web of Science ®Google Scholar
• USRDS. Costs of CKD and ESRD 2005. USRDS Annual Data Report. Minneapolis, MN: USRDS
   Google Scholar
• Dinneen S, Gerstein H. The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-8
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, van Hout B. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-28
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics 2003;21:941-50
   PubMed Web of Science ®Google Scholar